Cerezyme Imiglucerase for Injection

1. Indications and Usage
Gaucher Disease:
Long-term enzyme replacement therapy for patients with a confirmed diagnosis of non-neuropathic (Type 1) and chronic neuropathic (Type 3) Gaucher disease.
Target Symptoms: Treatment of anemia, thrombocytopenia, bone disease, and hepatosplenomegaly (enlarged liver and spleen).
2. Dosage and Administration
Route of Administration:
For Intravenous (IV) Infusion ONLY.
Recommended Dosage:
Individualized Dosing: Dosage is highly individualized based on disease severity and response.
Typical Range: Initial dosing typically ranges from 15 Units/kg administered every 2 weeks to 60 Units/kg administered every 2 weeks.
Titration: Dosage should be adjusted based on clinical response (e.g., reduction in spleen volume, increase in platelets).
Critical Administration Instructions:
Reconstitution: Reconstitute with Sterile Water for Injection (2 mL for 200 Unit vial; 10 mL for 400 Unit vial).
Dilution: Dilute the reconstituted solution in 0.9% Sodium Chloride Injection (100–200 mL).
Filtration: Use an in-line low-protein-binding 0.2 µm filter.
Infusion Time: Administer over 1–2 hours.
Stability: Do not freeze. Use immediately after reconstitution.
3. Mechanism of Action
Enzyme Replacement:
Imiglucerase is a recombinant form of the human enzyme beta-glucocerebrosidase.
Substrate Degradation:
It catalyzes the hydrolysis of glucocerebroside (a lipid) into glucose and ceramide within the lysosomes of macrophages.
Therapeutic Result: By restoring enzymatic activity, it clears the accumulated “Gaucher cells” (lipid-laden macrophages) from the liver, spleen, and bone marrow, reversing organomegaly and cytopenias.
4. Safety and Warnings
Hypersensitivity Reactions:
Serious hypersensitivity reactions (including anaphylaxis) have been reported.
Action: Monitor patients during infusion. Have appropriate medical support (e.g., epinephrine) available.
Immunogenicity:
Patients may develop IgG antibodies to imiglucerase.
Action: Monitor antibody titers, especially during the first year of therapy.
Pulmonary Hypertension:
Cases of pulmonary hypertension have been reported in patients treated with imiglucerase.
Contraindications: None listed, but caution is advised in patients with severe pulmonary hypertension.
5.Adverse Reactions
Most Common:
Infusion-associated reactions (fever, chills, headache, dizziness, nausea), fatigue, bone pain, and injection site reactions.
Note: Most reactions are mild to moderate and can often be managed by slowing the infusion rate or pre-medication.
6.Drug Interactions
No Clinical Significance:
No formal drug-drug interaction studies have been conducted. However, caution is advised when co-administering with other drugs that may cause hypersensitivity.
7.Pharmaceutical Information
Chemical Composition:
Active Ingredient: Imiglucerase.
Appearance: White to off-white lyophilized cake or powder.
Packaging: Single-dose vial (200 Units and 400 Units).
Storage: Store at 2°C to 8°C (36°F to 46°F).